BioCentury
ARTICLE | Clinical News

Invokana canagliflozin: Additional Phase III data

July 1, 2013 7:00 AM UTC

Additional data from the double-blind, international Phase III CANTATA-SU (DIA3009) trial in 1,450 Type II diabetics with inadequate glycemic control on maximally effective doses of metformin showed that once-daily 100 and 300 mg oral canagliflozin each led to a greater reduction in HbA1c from baseline to week 104 vs. glimepiride (0.65% and 0.74%, respectively, vs. 0.55%). Additionally, both doses of canagliflozin led to greater reductions in FPG (19.3 and 22.5 mg/dL, respectively, vs. 10.6 mg/dL), body weight (4.1% and 4.2%, respectively, vs. a gain of 0.9%) and SBP (2 and 3.1 mmHg, respectively, vs. a gain of 1.7 mmHg) vs. glimepiride. Additionally, 42.5% of patients receiving low-dose canagliflozin and 50.2% of patients receiving high-dose canagliflozin achieved an HbA1c of <7% at week 104 vs. 43.9% for glimepiride. Data were presented at the American Diabetes Association meeting in Chicago. ...